Patent ID: 11873512
Assignee: NATIONAL UNIVERSITY OF SINGAPORE
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. A method of producing a population of immune cells for use in treating cancer, said method comprising:
culturing a population of mononuclear cells comprising natural killer (NK) cells and T cells resulting in the resulting in the expansion of NK and T cells, and
introducing into the NK cells and the T cells a nucleic acid encoding a chimeric receptor comprising:
an extracellular receptor domain, wherein said extracellular receptor domain comprises a fragment of NKG2D that binds one or more of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6, and
a CD3 zeta cytoplasmic domain,

wherein upon binding of one or more of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6 to the extracellular receptor domain, the NK cells exhibit one or more of enhanced cytotoxicity and anti-tumor capacity against target cells, triggered signal transduction, triggered secretion of cytokines and chemokines, increased target cell apoptosis, and sustained cytotoxicity against target cells.